De Clercq Erik

Prof., Dr.
Born March 28, 1941

  • Member of Learned Society since 2021

Educational and professional preparation:

  • 1966: graduated as Medical Doctor (MD), KU Leuven (Belgium)
  • 1966-1970: specialization in Clinical Biology, KU Leuven
  • 1972: graduated as Philosophical Doctor (PhD), KU Leuven

Employment and academic positions:

  • 1966 – 1968: Research Assistant at Rega Institute for Medical Research (KU Leuven)
  • 1968 – 1970: Senior Research Assistant at Stanford University Medical School
  • 1977 – 2006: Full Professor at Faculty of Medicine, KU Leuven
  • 2006 – present: Professor Emeritus with duty
  • 2007 – present: teaches the course on “Biochemistry at the Service of Medicine” to Bachelor/Master students from the Universities of Česke Budějovice (Budweis) and Linz

Membership in selected domestic scientific bodies:

  • Belgian Society of Biochemistry and Molecular Biology (since 1972)
  • Belgian Society for Microbiology (since 1998)
  • Belgian Immunological Society (since 1977)
  • Infectious Diseases Society of the Netherlands and Flanders (since 1976)

Membership and positions in international organizations and societies:

  • Academia Europaea (since 1989)
  • American Association for the Advancement of Science (since 1969)
  • American Association for Cancer Research (since 1974)
  • American Association of Immunologists (since 1974)
  • American Chemical Society, Division of Biological Chemistry (since 1985)
  • American Chemical Society, Division of Medicinal Chemistry (since 1985)
  • American Federation for Medical Research (formerly: American Federation for Clinical Research) (since 1970)
  • American Society for Microbiology (since 1969)
  • American Society for Pharmacology and Experimental Therapeutics (Regular Member) (since 1982)
  • American Society of Tropical Medicine and Hygiene (since 1999)
  • Biochemical Society (UK) (since 1981)
  • European Academy of Sciences (since 2003)
  • European AIDS Clinical Society (since 1999)
  • European Association for Vision and Eye Research (since 1998)
  • European Society for Biochemical Pharmacology (since 1977)
  • European Society of Chemotherapy (Infectious Diseases) (since 1992)
  • European Society of Clinical Microbiology (since 1988)
  • European Society for Antiviral Research (ESAR) (since 2011)
  • European Society for Clinical Virology (since 1997; corresponding member since 2001)
  • European Society for Engineering and Medicine (since 1994)
  • Federation of American Societies for Experimental Biology (FASEB) (since 1982)
  • HIV Medicine Association (since 2001)
  • Infectious Diseases Society of America (since 1998)
  • Inter-American Society for Chemotherapy (since 1985)
  • International AIDS Society (since 1995)
  • International Cytokine Society (since 1998)
  • International Immunocompromised Host Society (since 1988)
  • International Pharmaceutical Federation (since 1993)
  • International Society for Antiviral Research (Founder Member of the Board of Directors of the Society in 1987; re-elected to the Board of Directors 1995, 1998)
  • International Society for Immunopharmacology (since 1991)
  • International Society for Infectious Diseases (since 1991)
  • International Society for Interferon and Cytokine Research (since 1992)
  • International Society for Nucleosides, Nucleotides and Nucleic Acids (sinds 2001)
  • International Society of Chemotherapy (since 1980)
  • Nederlandse Vereniging voor Microbiologie (since 1972)
  • Nederlandse Vereniging voor Farmaceutische Wetenschappen (since 1988)
  • New York Academy of Sciences (since 1980)
  • Paul-Ehrlich-Society for Chemotherapy (since 1986)
  • Society for Leukocyte Biology (formerly: Reticuloendothelial Society) (USA) (since 1970)
  • Société Française de Thérapeutique et de Pharmacologie Clinique (since 1990)
  • Society for Medicines Research (UK) (since 1990)
  • Society for Experimental Biology and Medicine (USA) (since 1970)
  • Society for General Microbiology (UK) (since 1971)

Notable awards:

  • Honorary doctor at the Universities of Ghent, Athens, Ferrara, Shandong, Prague, Česke Budějovice, Tours and Hull
  • Honorary citizen of the town of Hamme (Belgium)
  • Named inventor of the year (EU) in 2008
  • Laureate of the Dr. Paul Janssen Prize in 2010
  • International Society of Antimicrobial Chemotherapy (ISAC) Fellow (FISAC) in 2019

Selected publications:

  • De Clercq, E. & De Somer, P.
    Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid. Science, 173: 260-262 (1971)
  • De Clercq, E., Descamps, J., De Somer, P., Barr, P.J., Jones, A.S. & Walker, R.T.
    E-5-(2-Bromovinyl)-2'-deoxyuridine : a potent and selective an¬tiherpes agent.
    Proc. Nat. Acad. Sci. USA, 76: 2947-2951 (1979)
  • Derynck, R., Content, J., De Clercq, E., Volckaert, G., Tavernier, J., Devos, R. & Fiers, W.
    Isolation and structure of a human fibroblast interferon gene.
    Nature, 285: 542-547 (1980).
  • Derynck, R., Remaut, E., Saman, E., Stanssens, P., De Clercq, E., Content, J. & Fiers, W.
    Expression of the human fibroblast interferon gene in Escherichia coli.
    Nature, 287: 193-197 (1980)
  • Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W.
    Secretory proteins induced in human fibroblasts under conditions used for the production of interferon beta.
    Proc. Natl. Acad. Sci. USA, 79: 2768-2772 (1982)
  • De Clercq, E., Holý, A., Rosenberg, I., Sakuma, T., Balzarini, J. & Maudgal, P.C.
    A novel selective broad-spectrum anti-DNA virus agent.
    Nature, 323: 464-467 (1986)
  • Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M.J., Breslin, H.J., Raey-maeckers, A., Van Gelder, J., Woestenborghs, R., Heykants, J., Schellekens, K., Janssen, M.A.C., De Clercq E. & Janssen, P.A.J.
    Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
    Nature, 343: 470-474 (1990)
  • De Clercq, E., Yamamoto, N., Pauwels, R., Baba, M., Schols, D., Nakashima, H., Balzarini, J., Debyser, Z., Murrer, B.A., Schwartz, D., Thornton, D., Bridger, G., Fricker, S., Henson, G., Abrams, M. & Picker, D.
    Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.
    Proc. Natl. Acad. Sci. USA, 89: 5286-5290 (1992)
  • Donzella, G.A., Schols, D., Lin, S.W., Esté, J.A., Nagashima, K.A., Maddon, P.J., Allaway, G.P., Sakmar, T.P., Henson, G., De Clercq, E. & Moore, J.P.
    AMD3100, a small-molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
    Nat. Med., 4: 72-77 (1998)
  • De Clercq, E.
    Strategies in the design of antiviral drugs.
    Nat. Rev. Drug Discov., 1: 13-25 (2002)
  • De Clercq, E.
    The bicyclam AMD3100 story.
    Nat. Rev. Drug Discov., 2: 581-587 (2003)
  • De Clercq, E.
    Antivirals and antiviral strategies.
    Nat. Rev. Microbiol., 2: 704-720 (2004)
  • De Clercq, E. & Holý, A.
    Acyclic nucleoside phosphonates: a key class of antiviral drugs.
    Nat. Rev. Drug Discov., 4: 928-940 (2005)
  • De Clercq, E.
    Antiviral agents active against influenza A viruses.
    Nat. Rev. Drug Discov., 5: 1015-1025 (2006)
  • De Clercq, E.
    The design of drugs for HIV and HCV.
    Nat. Rev. Drug Discov., 6: 1001-1018 (2007)
  • Li, G.; De Clercq, E.
    Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
    Nat. Rev. Drug Discov. 19, 149-150, doi:10.1038/d41573-020-00016-0 (2020)

Visit the following website:   https://www.erikdeclercq.org/

 

Zpět na seznam článků

Novinky

05.06.22

Zjemnělá složitost: přednáška Michala Kouckého

Pozvánka na veřejnou přednášku 21. června 2022: Tradiční dělení výpočetních úloh na efektivně řešitelné a efektivně neřešitelné je příliš hrubé a neodráží naše reálné potřeby. Tzv. zjemnělá složitost se snaží předestřít jemnější obrázek skutečnosti a ukazuje překvapivou souvislost mezi oběma typy úloh.

02.06.22

Pavel Barša: Válka na Ukrajině – co předcházelo a co přijde

Záznam přednášky prof. Barši z Ústavu politologie Filozofické fakulty Univerzity Karlovy, kterou přednesl na XXVIII. valném shromáždění Učené společnosti České republiky 16. května 2022.

18.05.22

Novým předsedou Učené společnosti České republiky se stal Libor Grubhoffer

Učená společnost České republiky má nového předsedu. S účinností od 17. května 2022 se jím na dva roky stal prof. Libor Grubhoffer, dosavadní 1. místopředseda společnosti, bývalý rektor Jihočeské univerzity a stávající ředitel Biologického centra AV ČR. Střídá prof. Pavla Jungwirtha z Ústavu organické chemie a biochemie AV ČR.